A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

Column: This is how the Danish Medicines Council should strengthen its application process

Roche and Novartis have been behind almost 10 percent of all application submissions to the Danish Medicines Council since 2017. In a column, representatives from both firms point out three problems and make concrete proposals for how to improve the council’s work.
by Darine Ghanem, General Manager for Roche Pharma Denmark & Iceland, and Peter Drøidal, Country Manager for Denmark & Nordic Head Market Access at Novartis, translated by daniel pedersen

In 2021, the Danish Medicines Council processed 50 new drug applications. Unfortunately, the established allotted case processing time of 84 days was exceeded with every application. This is the fifth year in a row that case processing got behind schedule, according to the council’s latest year-in-review.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • Kasper Bødker Mejlvang, general manager for Denmark and Iceland at Novo Nordisk | Photo: Novo Nordisk / PR

    Novo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomings

    For subscribers

  • Photo: Jan Dagø/Jyllands-Posten/Ritzau Scanpix

    Danish Medicines Council recommends Genmab-developed sclerosis drug

    For subscribers

  • Photo: CHARLES PLATIAU/Reuters / X00217

    Novartis increases sales of Genmab-developed sclerosis drug

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Foto: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Foto: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


Foto: Tom Little
Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers


  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Foto: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


  • Foto: Mike Blake

    Eli Lilly's head of diabetes and obesity retires

    Mike Mason announces that he will retire at the end of the year after 34 years with the company.

    For subscribers


  • Foto: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


Further reading

Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers



Foto: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers


Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.


Novo Nordisk's manufacturing facility in Clayton, the US. | Photo: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers



Photo: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers


Jobs

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Clinical Trial Manager

  • Project Director, HR & ESG

  • QA/RA Manager

  • Senior QA Specialists (GMP or GCP)

  • Discovery Project Leader, Principal Scientist

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • Chemist for Incoming Materials in QC department

  • Director, Head of Antibody Technology

  • Senior CMC Specialist, Upstream Processing, Genmab

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Clinical Trial Manager

  • Project Director, HR & ESG

  • QA/RA Manager

  • Senior QA Specialists (GMP or GCP)

  • Discovery Project Leader, Principal Scientist

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • Chemist for Incoming Materials in QC department

  • Director, Head of Antibody Technology

  • Senior CMC Specialist, Upstream Processing, Genmab

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved